Alyeska Investment Group L.P. Acquires 250,000 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Alyeska Investment Group L.P. raised its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 23.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,334,696 shares of the company's stock after buying an additional 250,000 shares during the period. Alyeska Investment Group L.P. owned 1.89% of Nkarta worth $3,323,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NKTX. JPMorgan Chase & Co. grew its position in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after acquiring an additional 1,474,560 shares during the last quarter. Wasatch Advisors LP raised its holdings in Nkarta by 37.4% in the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock valued at $6,277,000 after buying an additional 686,229 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Nkarta by 101.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company's stock valued at $1,417,000 after acquiring an additional 286,181 shares during the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Nkarta by 23.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $1,992,000 after purchasing an additional 150,000 shares during the period. Finally, Barclays PLC increased its holdings in Nkarta by 161.4% in the third quarter. Barclays PLC now owns 232,566 shares of the company's stock valued at $1,051,000 after purchasing an additional 143,608 shares during the period. Institutional investors own 80.54% of the company's stock.

Nkarta Stock Up 5.4%

NKTX traded up $0.11 during trading on Monday, hitting $2.04. 151,183 shares of the company's stock were exchanged, compared to its average volume of 1,279,595. The stock has a market cap of $144.40 million, a P/E ratio of -1.08 and a beta of 0.81. The business's 50 day moving average is $1.78 and its two-hundred day moving average is $2.24. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. On average, sell-side analysts forecast that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NKTX shares. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Stifel Nicolaus lowered their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. Finally, Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Nkarta in a report on Wednesday, April 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $14.83.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.